Chemtura CORP Form 10-O November 13, 2006

X

0

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2006

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

to

(Commission File Number) 1-15339

CHEMTURA CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization) 52-2183153

(I.R.S. Employer Identification Number)

199 Benson Road, Middlebury, Connecticut

(Address of principal executive offices)

06749

(Zip Code)

(203) 573-2000

(Registrant s telephone number, including area code)

(Former name, former address and former fiscal year, if changed from last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

> x Yes o No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filed. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act (check one).

Large Accelerated Filer x

Accelerated Filer O

Non-accelerated filer O

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

o Yes

x No

The number of shares of common stock outstanding as of the latest practicable date is as follows:

Class

Common Stock - \$.01 par value

Number of shares outstanding at September 30, 2006 240,675,031

CHEMTURA CORPORATION AND SUBSIDIARIES FORM 10-Q FOR THE QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2006

| | <u>INDEX</u> | _ PAGE |
|------------------|---|--------|
| PART I. | FINANCIAL INFORMATION | |
| Item 1. | Financial Statements and Accompanying Notes | |
| | Condensed Consolidated Statements of Earnings (Unaudited) Quarter and nine months ended September 30, 2006 and 2005 | 2 |
| | Condensed Consolidated Balance Sheets September 30, 2006 (Unaudited) and December 31, 2005 | 3 |
| | Condensed Consolidated Statements of Cash Flows (Unaudited) Nine months ended September 30, 2006 and 2005 | 4 |
| | Notes to Condensed Consolidated Financial Statements (Unaudited) | 6 |
| | Report of Independent Registered Public Accounting Firm | 45 |
| Item 2. | Management s Discussion and Analysis of Financial Condition and Results of Operations | 46 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 68 |
| Item 4. | Controls and Procedures | 69 |
| <u>PART II</u> . | OTHER INFORMATION | |
| Item 1. | <u>Legal Proceedings</u> | 70 |
| Item 1A. | Risk Factors | 78 |
| Item 6. | <u>Exhibits</u> | 79 |
| | Signatures | 80 |
| 1 | | |
| | | |

PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements and Accompanying Notes

CHEMTURA CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Earnings (Unaudited) Quarter and nine months ended September 30, 2006 and 2005 (In thousands of dollars, except per share data)

| | Qua 2006 | rter ended | | 2005 | i | | Nine 2006 | months ende | ed | 2005 | i |
|---|-------------|------------|---|------|----------|-----|--------------|-------------|----|-----------------|-----------|
| Net sales | \$ | 917,011 | | \$ | 918,416 | | \$ | 2,849,095 | | \$ | 2,110,475 |
| | | | | | | | | | | | |
| Cost of products sold | 698 | | | 703, | | | - / | 3,248 | | | 6,085 |
| Selling, general and administrative | 103 | | | 101, | | | 307, | | | 227, | |
| Depreciation and amortization | 50,9 | | | 46,2 | | | 148, | | | 104, | |
| Research and development | 16,5 | 193 | | 15,5 | 82 | | 49,1 | | ` | 36,5 | |
| Facility closures, severance and related costs | 863 | | | 220 | | | (1,9) | |) | 24,2 | |
| Antitrust costs | 25,6 | | | 6,71 | | | 70,7 | | | 13,2 | |
| Merger costs | 1,10 |)2 | | 19,3 | | | 15,8 | 92 | | 28,0 | |
| In-process research and development | | | | 75,4 | .00 | | | | | 75,4 | .00 |
| (Gain) loss on sale of businesses, net | (113 | |) | | | | 12,3 | | | | |
| Income related to sale of Gustafson joint venture | (1,5 | |) | | | | (1,50 | |) | | |
| Impairment of non-current assets | 74,6 | | | | | | 80,2 | | | | |
| Equity income | (1,0 | |) | (602 | | | (1,54 | |) | (776 | |
| Operating profit (loss) | (51, | |) | (49, | | | 46,8 | | | 55,7 | |
| Interest expense | 22,4 | | | 29,1 | | | 80,8 | | | 77,8 | |
| Loss on early extinguishment of debt | 24,3 | | | 10,8 | | | 43,8 | | | 10,8 | |
| Other expense (income), net | 3,12 | .9 | | 1,92 | .3 | (| (2,38 | 85 |) | 7,57 | 2 |
| | | | | | | | | | | | |
| Loss from continuing operations before income | | | | | | | | | | | |
| taxes | (101 | 1,750 |) | (91, | 693 |) (| (75, | 518 |) | (40, 10) | 574) |
| Income tax expense (benefit) | (15, | 933 |) | 28,5 | 92 | (| (3,32) | 26 |) | 51,3 | 08 |
| | | | | | | | | | | | |
| Loss from continuing operations | (85, | 817 |) | (120 |),285 |) (| (72, | 192 |) | (91, | 882) |
| Earnings (loss) from discontinued operations | | | | (25 | |) | | | | 2,63 | 1 |
| Gain (loss) on sale of discontinued operations | 45,9 | 25 | | 1,38 | 8 | 4 | 45,9 | 25 | | (26, 1) | 234) |
| Net loss | \$ | (39,892 |) | \$ | (118,922 |) : | \$ | (26,267 |) | \$ | (115,485) |
| | | | | | | | | | | | |
| Basic earnings (loss) per common share: | | | | | | | | | | | |
| Loss from continuing operations | \$ | (0.36 |) | \$ | (0.51 |) : | \$ | (0.30 |) | \$ | (0.58) |
| Earnings (loss) from discontinued operations | | | | | | | | | | 0.02 | • |
| Gain (loss) on sale of discontinued operations | 0.19 | | | 0.01 | | (| 0.19 | | | $(0.1)^{\circ}$ | 7) |
| Net loss | \$ | (0.17 |) | \$ | (0.50) |) : | \$ | (0.11 |) | \$ | (0.73) |
| | | | | | | | | | | | |
| Diluted earnings (loss) per common share: | | | | | | | | | | | |
| Loss from continuing operations | \$ | (0.36 |) | \$ | (0.51 |) : | \$ | (0.30 |) | \$ | (0.58) |
| Earnings (loss) from discontinued operations | | | | | | | | | | 0.02 | |
| Gain (loss) on sale of discontinued operations | 0.19 | | | 0.01 | | (| 0.19 | | | $(0.1)^{\circ}$ | 7) |
| Net loss | \$ | (0.17 |) | \$ | (0.50 |) : | \$ | (0.11 |) | \$ | (0.73) |
| | | | | | | | | | | | |
| Dividends per common share | \$ | 0.05 | | \$ | 0.05 | | \$ | 0.15 | | \$ | 0.15 |

See accompanying notes to condensed consolidated financial statements.

CHEMTURA CORPORATION AND SUBSIDIARIES

Condensed Consolidated Balance Sheets September 30, 2006 (Unaudited) and December 31, 2005 (In thousands of dollars)

| | September 30, 2006 | December 31, 2005 |
|---|-----------------------|----------------------|
| ASSETS | | |
| | | |
| CURRENT ASSETS | | |
| Cash and cash equivalents | \$ 127,324 | \$ 138,556 |
| Accounts receivable | 308,183 | 547,857 |
| Inventories | 678,796 | 661,617 |
| Other current assets | 232,939 | 193,570 |
| Total current assets | 1,347,242 | 1,541,600 |
| NON CURRENT AGGETG | | |
| NON-CURRENT ASSETS | 1 142 600 | 1 100 225 |
| Property, plant and equipment, net | 1,142,600 | 1,192,335 |
| Cost in excess of acquired net assets | 1,188,967 | 1,211,459 |
| Intangible assets, net | 567,122 | 620,677 |
| Other assets | 372,586 | 419,932 |
| | \$ 4,618,517 | \$ 4,986,003 |
| LIABILITIES AND STOCKHOLDERS EQUITY | | |
| | | |
| CURRENT LIABILITIES | | |
| Short-term borrowings | \$ 49,929 | \$ 60,168 |
| Accounts payable | 267,233 | 310,485 |
| Accrued expenses | 407,675 | 444,336 |
| Income taxes payable | 134,013 | 160,700 |
| Total current liabilities | 858,850 | 975,689 |
| | | |
| NON-CURRENT LIABILITIES | | |
| Long-term debt | 1,069,059 | 1,309,603 |
| Pension and post-retirement health care liabilities | 576,642 | 618,539 |
| Other liabilities | 284,016 | 306,775 |
| CTOCKHOLDERG FOLUTY | | |
| STOCKHOLDERS EQUITY | 2.522 | 2.515 |
| Common stock | 2,522 | 2,515 |
| Additional paid-in capital | 3,001,904 | 2,950,649 |
| Accumulated deficit | | (869,873 |
| Accumulated other comprehensive loss | | (141,052 |
| Treasury stock at cost | | (166,842 |
| Total stockholders equity | 1,829,950 | 1,775,397 |
| | \$ 4,618,517 | \$ 4,986,003 |

See accompanying notes to condensed consolidated financial statements.

3

CHEMTURA CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited) Nine months ended September 30, 2006 and 2005 (In thousands of dollars)

| Net loss S | Increase (decrease) in cash | 2006 | 2005 |
|--|--|------------|----------------|
| Adjustments to reconcile net loss to net cash provided by (used in) operations: 12,362 | CASH FLOWS FROM OPERATING ACTIVITIES | | |
| 12,362 | Net loss | \$ (26,267 |) \$ (115,485) |
| Gain loss on sale of discontinued operations 15,000 | Adjustments to reconcile net loss to net cash provided by (used in) operations: | | |
| Income related to sale of Gustafson 1,500 | Loss on sale of businesses, net | 12,362 | |
| Impairment of non-current assets | (Gain) loss on sale of discontinued operations | (45,925 |) 26,234 |
| Loss on early extinguishment of debt | Income related to sale of Gustafson | (1,500 |) |
| Depreciation and amortization 148,261 106,887 100,79 3,291 100,700 10,200 10, | Impairment of non-current assets | 80,263 | |
| Stock-based compensation expense 10,079 3,291 Equity income (7,309 7776 78,400 Changes in assets and liabilities, net of assets acquired and liabilities assumed: | Loss on early extinguishment of debt | 43,897 | 10,859 |
| Equity income | Depreciation and amortization | 148,261 | 106,887 |
| In-process research and development | Stock-based compensation expense | 10,079 | 3,291 |
| Canages in assets and liabilities, net of assets acquired and liabilities assumed: Accounts receivable | Equity income | (7,309 |) (776) |
| Canages in assets and liabilities, net of assets acquired and liabilities assumed: Accounts receivable | In-process research and development | | 75,400 |
| Accounts receivable - securitization 213,759 (58,158 1) Inventories (4.659 45,195 45,195 46,200 46 | Changes in assets and liabilities, net of assets acquired and liabilities assumed: | | |
| Inventories | Accounts receivable | 51,414 | 112,878 |
| Accounts payable (48,798 095,699 0 000 000 000 000 000 000 000 000 0 | Accounts receivable - securitization | 213,759 | (58,158) |
| Deposit for civil antitrust settlement | Inventories | (4,659 |) 45,195 |
| Pensis for civil antitrust settlement (40,315) Pension and post-retirement health care liabilities (58,710) (47,750) (47,750) (48,617 | Accounts payable | (48,798 |) (95,699 |
| Pension and post-retirement health care liabilities (58,710) (47,750) (47,750) (20,505) | | | |
| Other (85,156) (48,617) (48,617) (26,056) Net cash provided by (used in) operations 281,711 (26,056)) CASH FLOWS FROM INVESTING ACTIVITIES 135,742 92,002 92,002 Acquisitions, net of cash acquired (6,734 69,405 Merger transaction costs paid (8,409) (16,360)) Capital expenditures (77,844 (58,303)))) Other investing activities 406 (56))))) Net cash provided by investing activities 43,161 (86,688) 86,688) </td <td></td> <td>(58,710</td> <td>) (47,750)</td> | | (58,710 |) (47,750) |
| Net cash provided by (used in) operations 281,711 (26,056) CASH FLOWS FROM INVESTING ACTIVITIES 135,742 92,002 Acquisitions, net of cash acquired (6,734 69,405 Merger transaction costs paid (8,409) (16,360) Capital expenditures (77,844) (58,303) Other investing activities 406 (56) Net cash provided by investing activities 43,161 86,688 CASH FLOWS FROM FINANCING ACTIVITIES (414,095 122,000 Payments on) proceeds from credit facility (414,095 122,000 Proceeds on long-term borrowings 497,262 9,000 Payments on short-term borrowings (323,689 (132,241) Payments on short-term borrowings (33,689 (132,241) Payment for debt issuance costs (5,775 (2,478) Dividends paid (36,065 (23,997) Repayment of life insurance policy loan (9,854) Proceeds from exercise of stock options 3,191 74,752 | | | |
| CASH FLOWS FROM INVESTING ACTIVITIES Net proceeds from divestments 135,742 92,002 Acquisitions, net of cash acquired (6,734 69,405 Merger transaction costs paid (8,409 (16,360) Capital expenditures (77,844 (58,303) Other investing activities 406 (56) Net cash provided by investing activities 43,161 86,688 CASH FLOWS FROM FINANCING ACTIVITIES (Payments on) proceeds from credit facility (414,095) 122,000 Proceeds on long-term borrowings 497,262 9,000 Payments on short-term borrowings (323,689) (132,241) Payments on short-term borrowings (13,963) (413) Premium paid on early extinguishment of debt (35,570) (3,323) Payment for debt issuance costs (5,775) (2,478) Dividends paid (36,065 (23,997) Repayment of life insurance policy loan (9,854) Proceeds from exercise of stock options 3,191 74,752 Other financing activities (2,177 < | Net cash provided by (used in) operations | | |
| Net proceeds from divestments 135,742 92,002 Acquisitions, net of cash acquired (6,734 69,405 Merger transaction costs paid (8,409) (16,360) Capital expenditures (77,844 (58,303) Other investing activities 406 (56) Net cash provided by investing activities 43,161 86,688 CASH FLOWS FROM FINANCING ACTIVITIES (Payments on) proceeds from credit facility (Payments on) proceeds from credit facility (Payments on long-term borrowings 497,262 9,000 Payments on short-term borrowings (323,689) (132,241) Payments on short-term borrowings (13,963) (413) Premium paid on early extinguishment of debt (35,570) (3,323) Payment for debt issuance costs (5,775) (2,478) Dividends paid (36,065) (23,997) Repayment of life insurance policy loan (9,854) Proceeds from exercise of stock options (9,854) Proceeds from exercise of stock options (9,854) Proceeds from exercise of stock options (3,191) (1,833) Net cash (used in) provided by financing activities (2,177) (1,833) Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period (138,556) 158,700 | | | |
| Net proceeds from divestments 135,742 92,002 Acquisitions, net of cash acquired (6,734 69,405 Merger transaction costs paid (8,409) (16,360) Capital expenditures (77,844 (58,303) Other investing activities 406 (56) Net cash provided by investing activities 43,161 86,688 CASH FLOWS FROM FINANCING ACTIVITIES (Payments on) proceeds from credit facility (Payments on) proceeds from credit facility (Payments on long-term borrowings 497,262 9,000 Payments on short-term borrowings (323,689) (132,241) Payments on short-term borrowings (13,963) (413) Premium paid on early extinguishment of debt (35,570) (3,323) Payment for debt issuance costs (5,775) (2,478) Dividends paid (36,065) (23,997) Repayment of life insurance policy loan (9,854) Proceeds from exercise of stock options (9,854) Proceeds from exercise of stock options (9,854) Proceeds from exercise of stock options (3,191) (1,833) Net cash (used in) provided by financing activities (2,177) (1,833) Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period (138,556) 158,700 | CASH FLOWS FROM INVESTING ACTIVITIES | | |
| Acquisitions, net of cash acquired (6,734 69,405 Merger transaction costs paid (8,409 1(1,360) Capital expenditures (77,844 0(58,303) Other investing activities 406 (56) Net cash provided by investing activities 43,161 86,688 CASH FLOWS FROM FINANCING ACTIVITIES (Payments on) proceeds from credit facility (414,095 122,000) Proceeds on long-term borrowings 497,262 9,000) Payments on long-term borrowings (323,689) (132,241) Payments on short-term borrowings (13,963) (413) Premium paid on early extinguishment of debt (35,570) (3,323) Payment for debt issuance costs (5,775) (2,478) Dividends paid (36,065) (23,997) Repayment of life insurance policy loan (9,854) Proceeds from exercise of stock options 3,191 74,752) Other financing activities (2,177) (1,833) Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents (4,631 (8,535) Change in cash and | | 135,742 | 92,002 |
| Merger transaction costs paid (8,409) (16,360) Capital expenditures (77,844) (58,303) Other investing activities 406 (56) Net cash provided by investing activities 43,161 86,688 CASH FLOWS FROM FINANCING ACTIVITIES (Payments on) proceeds from credit facility (414,095) 122,000 Proceeds on long-term borrowings 497,262 9,000 Payments on short-term borrowings (323,689) (132,241) Payments on short-term borrowings (13,963) (413) Premium paid on early extinguishment of debt (35,570) (3,323) Payment for debt issuance costs (5,775) (2,478) Dividends paid (36,065) (23,997) Repayment of life insurance policy loan (9,854) Proceeds from exercise of stock options 3,191 74,752 Other financing activities (2,177) (1,833) Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents 4,631 (8,535) Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period 138,556 1 | | (6,734 |) 69,405 |
| Capital expenditures (77,844) (58,303) Other investing activities 406 (56) Net cash provided by investing activities 43,161 86,688 CASH FLOWS FROM FINANCING ACTIVITIES (Payments on) proceeds from credit facility (414,095) 122,000 Proceeds on long-term borrowings 497,262 9,000 Payments on long-term borrowings (323,689) (132,241) Payments on short-term borrowings (13,963) (413) Premium paid on early extinguishment of debt (35,570) (3,323) Payment for debt issuance costs (5,775) (2,478) Dividends paid (36,065) (23,997) Repayment of life insurance policy loan (9,854) Proceeds from exercise of stock options 3,191 74,752 Other financing activities (2,177) (1,833) Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents 4,631 (8,535) Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period 138,556 158,700 | | • • |) (16,360 |
| Other investing activities 406 (56) Net cash provided by investing activities 43,161 86,688 CASH FLOWS FROM FINANCING ACTIVITIES (414,095) 122,000 (Payments on) proceeds from credit facility (414,095) 122,000 Proceeds on long-term borrowings 497,262 9,000 Payments on long-term borrowings (323,689) (132,241) Payments on short-term borrowings (13,963) (413) Premium paid on early extinguishment of debt (35,570) (3,323) Payment for debt issuance costs (5,775) (2,478) Dividends paid (36,065) (23,997) Repayment of life insurance policy loan (9,854) Proceeds from exercise of stock options 3,191 74,752 Other financing activities (2,177) (1,833) Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents 4,631 (8,535) Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period 138,556 158,700 | | | |
| Net cash provided by investing activities 43,161 86,688 CASH FLOWS FROM FINANCING ACTIVITIES (Payments on) proceeds from credit facility (414,095 122,000 Proceeds on long-term borrowings 497,262 9,000 Payments on short-term borrowings (323,689) (132,241) Payments on short-term borrowings (13,963) (413) Premium paid on early extinguishment of debt (35,570) (3,323) Payment for debt issuance costs (5,775) (2,478) Dividends paid (36,065) (23,997) Repayment of life insurance policy loan (9,854) Proceeds from exercise of stock options 3,191 74,752 Other financing activities (2,177) (1,833) Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents 4,631 (8,535) Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period 138,556 | | | |
| CASH FLOWS FROM FINANCING ACTIVITIES (Payments on) proceeds from credit facility (414,095) 122,000 Proceeds on long-term borrowings 497,262 9,000 Payments on long-term borrowings (323,689) (132,241) Payments on short-term borrowings (13,963) (413) Premium paid on early extinguishment of debt (35,570) (3,323) Payment for debt issuance costs (5,775) (2,478) Dividends paid (36,065) (23,997) Repayment of life insurance policy loan (9,854) Proceeds from exercise of stock options 3,191 74,752 Other financing activities (2,177) (1,833) Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents 4,631 (8,535) Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period 138,556 158,700 | | 43,161 | |
| (Payments on) proceeds from credit facility (414,095) 122,000 Proceeds on long-term borrowings 497,262 9,000 Payments on long-term borrowings (323,689) (132,241) Payments on short-term borrowings (13,963) (413) Premium paid on early extinguishment of debt (35,570) (3,323) Payment for debt issuance costs (5,775) (2,478) Dividends paid (36,065) (23,997) Repayment of life insurance policy loan (9,854) Proceeds from exercise of stock options 3,191 74,752 Other financing activities (2,177) (1,833) Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents 4,631 (8,535) Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period 138,556 158,700 | | | |
| Proceeds on long-term borrowings 497,262 9,000 Payments on long-term borrowings (323,689) (132,241) Payments on short-term borrowings (13,963) (413) Premium paid on early extinguishment of debt (35,570) (3,323) Payment for debt issuance costs (5,775) (2,478) Dividends paid (36,065) (23,997) Repayment of life insurance policy loan (9,854) Proceeds from exercise of stock options 3,191 74,752 Other financing activities (2,177) (1,833) Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents 4,631 (8,535) Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period 138,556 158,700 | CASH FLOWS FROM FINANCING ACTIVITIES | | |
| Payments on long-term borrowings (323,689) (132,241) Payments on short-term borrowings (13,963) (413) Premium paid on early extinguishment of debt (35,570) (3,323) Payment for debt issuance costs (5,775) (2,478) Dividends paid (36,065) (23,997) Repayment of life insurance policy loan (9,854) Proceeds from exercise of stock options 3,191 74,752 Other financing activities (2,177) (1,833) Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents 4,631 (8,535) Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period 138,556 158,700 | (Payments on) proceeds from credit facility | (414,095 |) 122,000 |
| Payments on short-term borrowings (13,963) (413) Premium paid on early extinguishment of debt (35,570) (3,323) Payment for debt issuance costs (5,775) (2,478) Dividends paid (36,065) (23,997) Repayment of life insurance policy loan (9,854) Proceeds from exercise of stock options (3,191 74,752) Other financing activities (2,177) (1,833) Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents (4,631 (8,535) Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period 138,556 158,700 | Proceeds on long-term borrowings | 497,262 | 9,000 |
| Payments on short-term borrowings (13,963) (413) Premium paid on early extinguishment of debt (35,570) (3,323) Payment for debt issuance costs (5,775) (2,478) Dividends paid (36,065) (23,997) Repayment of life insurance policy loan (9,854) Proceeds from exercise of stock options (3,191 74,752) Other financing activities (2,177) (1,833) Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents (4,631 (8,535) Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period 138,556 158,700 | Payments on long-term borrowings | (323,689 |) (132,241) |
| Premium paid on early extinguishment of debt Payment for debt issuance costs (5,775) (2,478) Dividends paid (36,065) (23,997) Repayment of life insurance policy loan Proceeds from exercise of stock options Other financing activities (2,177) (1,833) Net cash (used in) provided by financing activities CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period | | (13,963 | |
| Payment for debt issuance costs (5,775) (2,478) Dividends paid (36,065) (23,997) Repayment of life insurance policy loan (9,854) Proceeds from exercise of stock options (3,191 74,752) Other financing activities (2,177) (1,833) Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents (4,631 (8,535) Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period 138,556 158,700 | Premium paid on early extinguishment of debt | (35,570 |) (3,323 |
| Dividends paid (36,065) (23,997) Repayment of life insurance policy loan (9,854) Proceeds from exercise of stock options 3,191 74,752 Other financing activities (2,177) (1,833) Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents 4,631 (8,535) Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period 138,556 158,700 | | (5,775 |) (2,478 |
| Repayment of life insurance policy loan (9,854) Proceeds from exercise of stock options 3,191 74,752 Other financing activities (2,177) (1,833) Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents 4,631 (8,535) Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period 138,556 158,700 | | | |
| Proceeds from exercise of stock options 3,191 74,752 Other financing activities (2,177) (1,833) Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents 4,631 (8,535) Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period 138,556 158,700 | Repayment of life insurance policy loan | |) |
| Other financing activities (2,177) (1,833) Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents 4,631 (8,535) Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period 138,556 158,700 | | | 74,752 |
| Net cash (used in) provided by financing activities (340,735) 41,467 CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents 4,631 (8,535) Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period 138,556 158,700 | | (2,177 |) (1,833 |
| CASH AND CASH EQUIVALENTS Effect of exchange rates on cash and cash equivalents Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period 138,556 158,700 | | | |
| Effect of exchange rates on cash and cash equivalents4,631(8,535)Change in cash and cash equivalents(11,232) 93,564Cash and cash equivalents at beginning of period138,556158,700 | | | |
| Effect of exchange rates on cash and cash equivalents4,631(8,535)Change in cash and cash equivalents(11,232)93,564Cash and cash equivalents at beginning of period138,556158,700 | CASH AND CASH EQUIVALENTS | | |
| Change in cash and cash equivalents (11,232) 93,564 Cash and cash equivalents at beginning of period 138,556 158,700 | | 4,631 | (8,535) |
| Cash and cash equivalents at beginning of period 138,556 158,700 | | | |
| | | | |
| | | | |

CHEMTURA CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited) - Continued Nine months ended September 30, 2006 and 2005 (In thousands of dollars)

| | 2005 |
|--|--------------|
| SUPPLEMENTAL SCHEDULE FOR NON-CASH INVESTING TRANSACTIONS: | |
| Fair value of non-cash assets acquired in acquisition | \$ 2,768,012 |
| Cash acquired in acquisition | 125,747 |
| In-process research and development | 75,400 |
| Issuance of common stock in acquisition, net of registration costs | (1,852,624) |
| Treasury stock acquired | 166,842 |
| Liabilities assumed in acquisition | \$ 1,283,377 |

See accompanying notes to condensed consolidated financial statements.

5

CHEMTURA CORPORATION AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

On July 1, 2005, Crompton Corporation (Crompton) and Great Lakes Chemical Corporation (Great Lakes) combined their businesses by merging a wholly-owned subsidiary of Crompton with and into Great Lakes (the Merger). Under the terms of the merger agreement, Great Lakes shareholders received 2.2232 shares of the Company s common stock for each share of Great Lakes common stock and Great Lakes became a wholly-owned subsidiary of Crompton. The Company also changed its name to Chemtura Corporation.

ACCOUNTING POLICIES

Presentation of Condensed Consolidated Financial Statements

The information in the foregoing condensed consolidated financial statements for the quarter and nine months ended September 30, 2006 and September 30, 2005 are unaudited, but reflect all adjustments which, in the opinion of management, are necessary for a fair presentation of the results of operations for the interim periods presented. All such adjustments are of a normal recurring nature, except as otherwise disclosed in the accompanying notes to the condensed consolidated financial statements.

The foregoing condensed consolidated financial statements include the accounts of Chemtura Corporation and the wholly-owned and majority-owned subsidiaries that it controls, including the results of operations of Great Lakes commencing July 1, 2005, which are collectively referred to as the Company. Other affiliates in which the Company has a 20% to 50% ownership interest or a non-controlling majority interest are accounted for in accordance with the equity method. All significant intercompany balances and transactions have been eliminated in consolidation.

On June 24, 2005, the Refined Products business was sold to Sun Capital Partners Group, Inc. Accordingly, the accompanying condensed consolidated financial statements for 2005 reflect the results of the Refined Products business as earnings from discontinued operations (net of tax) through the date of the sale. The condensed consolidated statements of cash flows have not been adjusted to separately reflect the discontinued operation and thus include the cash flows of the Refined Products business through the sale date. Refer to the discontinued operations footnote for further information.

Certain financial information and footnote disclosures included in the annual financial statements have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission for reporting on Form 10-Q. The interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company s 2005 Annual Report on Form 10-K. The consolidated results of operations for the nine months ended September 30, 2006 are not necessarily indicative of the results expected for the full year.

Operating Costs and Expenses

Cost of products sold includes all costs incurred in manufacturing products, including raw materials, direct manufacturing costs and manufacturing overhead. Cost of products sold also includes warehousing; distribution; engineering (other than polymer processing equipment design engineering); purchasing; customer service and environmental, health and safety functions, and shipping and handling costs for outbound product shipments. Selling, general and administrative expense (SG&A) includes costs and expenses related to the following functions and activities: selling, advertising, polymer processing equipment design engineering, information technology, legal, provision for doubtful accounts, corporate facilities and corporate administration. SG&A also includes accounting, finance and human resources, excluding direct support in manufacturing operations, which is included as cost of products sold. Research and development expenses (R&D) include basic and applied research and development activities of a technical and non-routine nature. R&D costs are expensed as incurred. Costs of products sold, SG&A and R&D expenses exclude depreciation and amortization expenses, which are presented on a separate line in the condensed consolidated statements of earnings.

Also included in cost of products sold for the third quarter and nine months ended September 30, 2005 is \$37.1 million related to the fair value impact of purchase accounting on inventory resulting from the Merger.

Other (Income) and Expenses

The following table is a summary of the (income) and expense items included on the other expense (income), net line in the condensed consolidated statements of earnings for all periods presented.

| | Quarter ended September 30, | | Nine months ended September 30, | | |
|--|-----------------------------|----------|---------------------------------|------------|--|
| (In thousands) | 2006 | 2005 | 2006 | 2005 | |
| Costs of securitization programs and other accounts receivable | | | | | |
| financing | \$ 4,181 | \$ 3,289 | \$ 11,005 | \$ 9,846 | |
| Equity (income) loss Davis Standard LLC | (2,790 | (395 |) (5,764 |) 248 | |
| Favorable settlement of contractual matter | | | (4,300 |) | |
| Foreign exchange (gain)/ loss | 3,171 | (590 |) 2,065 | (728 | |
| Interest income | (900 | (2,742 |) (7,701 |) (7,634 | |
| Minority interest | (945 | 1,651 | 2,239 | 3,703 | |
| Pension and other post-retirement benefits of legacy Witco | | | | | |
| businesses | 80 | 712 | 240 | 2,138 | |
| Other items, individually less than \$1,000 | 332 | (2 |) (169 |) (1 | |
| Other (income) expense, net | \$ 3,129 | \$ 1,923 | \$ (2,385 |) \$ 7,572 | |

The interest income for the nine months ended September 30, 2006 and the nine months ended September 30, 2005 include interest income resulting from tax settlements of \$4.0 million and \$2.2 million, respectively.

Pension and other post-retirement benefits of legacy Witco plans represents the accretion of interest on obligations assumed in connection with the purchase of Witco in 1999 relating to businesses for which the Company and the plan participants did not have any continuing involvement either prior or subsequent to the acquisition.

Other Items

Included in cash and cash equivalents in the Company s condensed consolidated balance sheets at September 30, 2006 and December 31, 2005, are \$2.5 million and \$2.4 million, respectively, of restricted cash that is required to be on deposit to support certain letters of credit and performance guarantees, the majority of which will be settled within one year. There are no additional legal restrictions on these cash balances. In addition, at September 30, 2006, the Company had approximately \$7.0 million in an escrow account that is restricted to pay existing antitrust settlement liabilities, which has been recorded in other current assets in the condensed consolidated balance sheet.

Included in accounts receivable are allowances for doubtful accounts of \$28.6 million at September 30, 2006 and \$30.5 million at December 31, 2005.

Accumulated depreciation amounted to \$1,006.7 million at September 30, 2006 and \$861.7 million at December 31, 2005.

During the first nine months of 2006 and 2005, the Company made interest payments of approximately \$81.2 million and \$90.6 million, respectively. The decrease was primarily due to the tendering of the Senior Floating Rate Notes due 2010 and the tendering of the 9.875% Senior Notes due 2012, partially offset by the inclusion of the debt of Great Lakes. During the first nine months of 2006 and 2005, the Company made payments for income taxes (net of refunds) of \$54.7 million and \$29.1 million, respectively.

RECLASSIFICATIONS

In the third quarter of 2006, the Company reclassified certain amounts related to operations from other (income) expense, net to SG&A, (gain) loss on sale of businesses, net and income related to the sale of Gustafson joint venture in the condensed consolidated statement of earnings. The items reclassified include (a) legacy Witco pension and other post-retirement benefit obligations related to businesses for which the Company has continuing involvement, (b) gains and losses on the sale of businesses which did not meet the criteria to be considered discontinued operations and (c) gains on the sale of equity method investees for which income had previously been reported within operating profit (loss). Although the Company properly classified these items within earnings (loss) from continuing operations, the Company improperly did not include these items as a component of operating profit (loss) in prior periods.

The following tables represent the effect of these reclassifications on prior period interim financial statements for all periods previously reported in 2006 and 2005. Additionally, the Company has provided the effect of such reclassifications on previously reported financial statements for the years ended December 31, 2005, 2004 and 2003.

The effect of the 2006 reclassification on the consolidated statements of earnings for the prior quarters and first six months of 2006 is as follows:

Other Items 12

7

Other Items 13

| | Periods Ended in | Periods Ended in 2006 | | | |
|--------------------------------------|------------------|-----------------------|------------|--|--|
| | Three-Months | Three Months | Six Months | | |
| (In thousands) | March 31, | June 30, | June 30, | | |
| Increase to SG&A | \$ 130 | \$ 128 | \$ 258 | | |
| (Gain) loss on sale of business, net | | 12,475 | 12,475 | | |
| Decrease to operating profit | \$ | | | | |

Other Items 14